Branded ear care products in Europe: regulatory pathways and scalable OTC market entry

The European consumer health market presents a compelling opportunity for companies seeking to expand their ear care portfolios. Demand for non-prescription ear care solutions is growing steadily, driven by ageing populations, increased hearing device use, and a broader cultural shift towards preventive self-care. Yet for organisations planning market entry, the European landscape can appear dauntingly complex. Regulatory classification varies by product type, commercial timelines differ markedly depending on the development model chosen, and the consequences of misclassification are costly. Evaluating how to bring a clinically validated, market-ready ear care range to a territory, understanding the regulatory and commercial framework is the single most important factor in determining speed to market and long-term portfolio viability.

EU classification of ear care products: medical device vs cosmetic vs prescription medicines

The first decision any ear care company must make when entering European markets is determining the correct regulatory classification for its product. This defines the entire commercialisation pathway, the evidence requirements, and the permissible product claims. Under EU law, ear care products typically fall into one of three categories:

• Medical devices are governed by Regulation (EU) 2017/745 / MDR. Products acting by physical means, such as moisture-control sprays or cerumenolytic solutions, are typically Class I devices requiring an EU Declaration of Conformity and technical documentation. In December 2025, the European Commission proposed a targeted simplification of the MDR (COM(2025)1023) to reduce administrative burden and modernise procedures, with current obligations remaining fully in force.

• Cosmetic products are governed by Regulation (EC) No 1223/2009. Applicable to products acting exclusively on the surface of the auricle (the visible outer ear) with no contact with the ear canal and no therapeutic claim. Any product entering the ear canal or making a functional claim shifts the classification towards medical device or medicinal product territory.

• Prescription medicines involve the most demanding pathway. Products that exert a pharmacological, immunological, or metabolic action fall under Directive 2001/83/EC and require a full marketing authorisation or registration via national competent authorities.

Correct classification from the outset prevents costly reclassification exercises and protects the integrity of clinical claims, an area of increasing scrutiny from national competent authorities across Europe.

Regulatory steps to commercialise ear care products across European markets

Once classification is established, the commercialisation pathway becomes considerably more predictable. For the most common category (Class I medical devices), the process under the current MDR involves:

• Technical documentation compiled in accordance with MDR Annex II and III, including clinical evaluation, risk management (ISO 14971), and usability evidence.

• EU Declaration of Conformity issued by the manufacturer, affirming compliance with the applicable General Safety and Performance Requirements.

• Registration in EUDAMED, the European database on medical devices, which has been progressively mandated and is subject to further rollout under the 2024 and 2025 regulatory amendments.

• Appointment of an Authorised Representative for manufacturers located outside the EU.

• National requirements, which can include additional language requirements, specific labelling obligations, or local registration.

The Commission’s December 2025 simplification proposal specifically targets steps such as EUDAMED registration and documentation procedures, with the stated aim of reducing duplication and lowering compliance costs.

For cosmetic products, the Cosmetic Products Notification Portal (CPNP) notification must be completed before placing the product on the market in any EU member state. The Responsible Person bears legal accountability for compliance, making partner selection a regulatory decision as much as a commercial one.

A critical consideration for health care in Europe is that CE marking under the MDR confers market access across all 27 EU member states, making it an efficient mechanism for pan-European launch once achieved. Products backed by robust clinical evidence and clear physical modes of action consistently present the most favourable regulatory profile for broad European deployment.

Branded products vs in-house development in ear care: timelines, costs, and risks

For companies without existing manufacturing infrastructure, the choice between distributing a clinically validated branded ear care product and developing in-house is largely a question of risk appetite, resource allocation and timeline.

• In-house development typically requires three to five years and significant capital investment before the first unit reaches pharmacy shelves. The regulatory burden is borne entirely by the developing company, and any gap in clinical evidence or manufacturing quality can halt the process entirely.

• Distributing an established, branded ear care solution removes the heaviest barriers to market entry. Clinical evaluation, technical documentation, and CE marking are already in place. The commercial partner focuses on channel access and market development, without formulation or regulatory risk, and with clinical heritage and brand reputation built in.

For consumer health companies seeking to build a differentiated ear care solution portfolio without the overhead of in-house R&D, partnering around an established branded product consistently outperforms commodity or generic alternatives in the pharmacy channel.

Market entry models for ear care products in Europe: distributor agreements, licensing, and multi-market rollout

European market entry for ear care products does not follow a single template. The optimal model depends on the company’s existing infrastructure, regulatory capability, and commercial ambitions.

• Distribution agreements are the most straightforward entry route. A local entity takes on the commercialisation of a CE-marked branded product (managing pharmacy channel access, local marketing, and MDR distributor obligations), bringing a fully validated ear care range to market under a recognised brand, without the cost or delay of independent product development.

• Licensing arrangements are better suited to organisations with existing manufacturing capabilities that seek access to validated formulations or technology platforms, or to situations where territorial complexity makes direct distribution impractical. Licensing typically involves longer negotiation timelines and more complex IP considerations than a straightforward distribution agreement.

• Multi-market rollout through a single validated product platform is one of the most commercially efficient strategies in ear care in Europe. A CE-marked product can be adapted for multiple EU markets (territory-specific labelling and language requirements aside) without separate regulatory submissions in each country. Clinical evidence and healthcare professional endorsement do the rest, building brand loyalty that generic alternatives cannot easily replicate.

Across all entry models, the strength of the originating product (its clinical foundation, manufacturing standards, and brand positioning) is the primary determinant of long-term commercial success.

At Mitelos, we offer a wide range of clinically validated ear care products, covering moisture control, earwax management, and ear canal protection.

For partners seeking scalable European market entry, we provide established brand equity, full regulatory documentation, and dedicated commercial support across key territories. 

Speak with our partnering team to explore how we can strengthen your ear care portfolio.

References

European Commission. Cosmetic products – specific topics [Internet]. Brussels: European Commission, Internal Market, Industry, Entrepreneurship and SMEs; [cited 2026 May 11]. Available from: https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-products-specific-topics_en

European Commission. Medical device classification [Internet]. Brussels: European Commission UDI Helpdesk; 2024 Oct 25 [cited 2026 May 11]. Available from: https://webgate.ec.europa.eu/udi-helpdesk/en/other-relevant-information/medical-device-classification.html

European Commission. New regulations – medical devices sector [Internet]. Brussels: European Commission, Directorate-General for Health and Food Safety; [cited 2026 May 11]. Available from: https://health.ec.europa.eu/medical-devices-sector/new-regulations_en

European Medicines Agency. Pre-authorisation guidance [Internet]. Amsterdam: EMA; [cited 2026 May 11]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/pre-authorisation-guidance

European Parliament, Council of the European Union. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Off J Eur Union. 2017;L 117:1–175. Available from: https://eur-lex.europa.eu/eli/reg/2017/745/2024-07-09